Evan F. Lind

Dr. Evan F. Lind


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2018 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
ALAdam J. Lamble
Adam J. Lamble
ELEvan F. Lind
Evan F. Lind
Immunotherapies, such as chimeric antigen receptor T cells, bispecific antibodies, and immune checkpoint inhibitors, have emerged as promising modalities in multiple hematologic malignancies. Despite the excitement surrounding immunotherapy, it is currently not possible to predict which patients will respond. Within solid tumors, the status of the immune microenvironment provides valuable insight regarding potential responses to immune therapies. Much less is known about the immune microenvironment within hematologic malignancies but the characteristics of this environment are likely to serve a similar predictive role. Acute myeloid leukemia (AML) is the most common hematologic malignancy in adults, and only 25% of patients are alive 5 years following their diagnosis. There is evidence that manipulation of the immune microenvironment by leukemia cells may play a role in promoting therapy resistance and disease relapse. In addition, it has long been documented that through modulation of the immune system following allogeneic bone marrow transplant, AML can be cured, even in patients with the highest risk disease. These concepts, along with the poor prognosis associated with this disease, have encouraged many groups to start exploring the utility of novel immune therapies in AML. While the implementation of these therapies into clinical trials for AML has been supported by preclinical rationale, many questions still exist surrounding their efficacy, tolerability, and the overall optimal approach. In this review, we discuss what is known about the immune microenvironment within AML with a specific focus on T cells and checkpoints, along with their implications for immune therapies.

8 June 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ALAdam J. Lamble
Adam J. Lamble
YKYoko Kosaka
Yoko Kosaka
TLTed Laderas
Ted Laderas
AMAllie Maffit
Allie Maffit
AKAndy Kaempf
Andy Kaempf
ELEvan F. Lind
Evan F. Lind
Significance: Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with a 5-y survival of 29%. Immunotherapy is based on the premise that tumors suppress the immune system. We investigated the status of T cell immunity in AML at the time of diagnosis. We found a significant association between T cell percentage in the bone marrow and overall survival in newly diagnosed AML patients. When we evaluated the T cells from the bone marrow of patients with AML, one-third displayed profound functional impairment. Most of these compromised T cells, however, could be rescued using checkpoint inhibitors. Our results support the development of immune checkpoint therapy to combat this deadly disease.

21 January 2023 in Leukemia
Verified
Journal Article
Open access
PDF file
KRKyle A. Romine
Kyle A. Romine
KMKevin MacPherson
Kevin MacPherson
HCHyun-Jun Cho
Hyun-Jun Cho
YKYoko Kosaka
Yoko Kosaka
PFPatrick A. Flynn
Patrick A. Flynn
ELEvan F. Lind
Evan F. Lind
Many acute myeloid leukemia (AML) patients exhibit hallmarks of immune exhaustion, such as increased myeloid-derived suppressor cells, suppressive regulatory T cells and dysfunctional T cells. Similarly, we have identified the same immune-related features, including exhausted CD8+ T cells (TEx) in a mouse model of AML. Here we show that inhibitors that target bromodomain and extra-terminal domain (BET) proteins affect tumor-intrinsic factors but also rescue T cell exhaustion and ICB resistance. Ex vivo treatment of cells from AML mice and AML patients with BET inhibitors (BETi) reversed CD8+ T cell exhaustion by restoring proliferative capacity and expansion of the more functional precursor-exhausted T cells. This reversal was enhanced by combined BETi and anti-PD1 treatment. BETi synergized with anti-PD1 in vivo, resulting in the reduction of circulating leukemia cells, enrichment of CD8+ T cells in the bone marrow, and increase in expression of Tcf7, Slamf6, and Cxcr5 in CD8+ T cells. Finally, we profiled the epigenomes of in vivo JQ1-treated AML-derived CD8+ T cells by single-cell ATAC-seq and found that JQ1 increases Tcf7 accessibility specifically in Tex cells, suggesting that BETi likely acts mechanistically by relieving repression of progenitor programs in Tex CD8+ T cells and maintaining a pool of anti-PD1 responsive CD8+ T cells.

16 March 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
SBScott Best
Scott Best
VLVi Lam
Vi Lam
TLTingting Liu
Tingting Liu
NBNur Bruss
Nur Bruss
AKAdam Kittai
Adam Kittai
ADAlexey V. Danilov
Alexey V. Danilov

1 February 2018 in Journal of Immunological Methods
Verified
Journal Article
Closed access
ALAdam J. Lamble
Adam J. Lamble
MDMatthew Dietz
Matthew Dietz
TLTed Laderas
Ted Laderas
SMShannon McWeeney
Shannon McWeeney
ELEvan F. Lind
Evan F. Lind

22 October 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
KMKaycee B. Moshofsky
Kaycee B. Moshofsky
HCHyun J. Cho
Hyun J. Cho
GWGuanming Wu
Guanming Wu
KRKyle A. Romine
Kyle A. Romine
MNMatthew T. Newman
Matthew T. Newman
ELEvan F. Lind
Evan F. Lind
Acute myeloid leukemia (AML) remains difficult to treat due to mutational heterogeneity and the development of resistance to therapy. Targeted agents, such as MEK inhibitors, may be incorporated into treatment; however, the impact of MEK inhibitors on the immune microenvironment in AML is not well understood. A greater understanding of the implications of MEK inhibition on immune responses may lead to a greater understanding of immune evasion and more rational combinations with immunotherapies. This study describes the impact of trametinib on both T cells and AML blast cells by using an immunosuppressive mouse model of AML and primary patient samples. We also used a large AML database of functional drug screens to understand characteristics of trametinib-sensitive samples. In the mouse model, trametinib increased T-cell viability and restored T-cell proliferation. Importantly, we report greater proliferation in the CD8+CD44+ effector subpopulation and impaired activation of CD8+CD62L+ naive cells. Transcriptome analysis revealed that trametinib-sensitive samples have an inflammatory gene expression profile, and we also observed increased programmed cell death ligand 1 (PD-L1) expression on trametinib-sensitive samples. Finally, we found that trametinib consistently reduced PD-L1 and PD-L2 expression in a dose-dependent manner on the myeloid population. Altogether, our data present greater insight into the impact of trametinib on the immune microenvironment and characteristics of trametinib-sensitive patient samples.